Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | FLT3 |
| Variant | F590_Y591delinsGD |
| Impact List | indel |
| Protein Effect | gain of function |
| Gene Variant Descriptions | FLT3 F590_Y591delinsGD results in a deletion of 2 amino acids in the juxtamembrane domain of the Flt3 protein from amino acids 590 to 591, combined with the insertion of a glycine (G) and an aspartic acid (D) at the same site (PMID: 11756186). F590_Y591delinsGD results in constitutive phosphorylation of Flt3, activation of Stat5 signaling, and transformation of cells in culture (PMID: 16410449). |
| Associated Drug Resistance | |
| Category Variants Paths |
FLT3 mutant FLT3 act mut FLT3 F590_Y591delinsGD FLT3 mutant FLT3 exon14 FLT3 F590_Y591delinsGD |
| Transcript | NM_004119.3 |
| gDNA | chr13:g.28034146_28034151delinsGTCACC |
| cDNA | c.1768_1773delinsGGTGAC |
| Protein | p.F590_Y591delinsGD |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_004119 | chr13:g.28034146_28034151delinsGTCACC | c.1768_1773delinsGGTGAC | p.F590_Y591delinsGD | RefSeq | GRCh38/hg38 |
| NM_004119.2 | chr13:g.28034146_28034151delinsGTCACC | c.1768_1773delinsGGTGAC | p.F590_Y591delinsGD | RefSeq | GRCh38/hg38 |
| NM_004119.3 | chr13:g.28034146_28034151delinsGTCACC | c.1768_1773delinsGGTGAC | p.F590_Y591delinsGD | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 F590_Y591delinsGD | hematologic cancer | sensitive | Gilteritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 F590_Y591delinsGD in culture (PMID: 40196870). | 40196870 |
| FLT3 F590_Y591delinsGD | hematologic cancer | sensitive | Quizartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 F590_Y591delinsGD in culture (PMID: 40196870). | 40196870 |
| FLT3 F590_Y591delinsGD | hematologic cancer | sensitive | Midostaurin | Preclinical - Cell culture | Actionable | In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 F590_Y591delinsGD in culture (PMID: 40196870). | 40196870 |